Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)

Ichiro Nakamura*, Hiroshi Maegawa, Kazuyuki Tobe, Satoshi Uno

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study (Advances in Therapy, (2019), 36, 4, (923-949), 10.1007/s12325-019-0895-1)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science